AIDS Therapy

Data on Lexiva/Ritonavir vs. Nelfinavir study published

Published in AIDS Weekly, July 26th, 2004

The protease inhibitor (PI) Lexiva (fosamprenavir calcium) dosed with ritonavir (Lexiva/r) once-daily (QD) as part of a first-line ART regimen provided antiviral suppression that was comparable in this single study to the PI nelfinavir (NFV) dosed twice-daily (BID), according to 48-week data from the SOLO trial published in the journal AIDS.

Both regimens were generally well tolerated, according to the study's authors. Lexiva (formerly GW433908, or 908), the first PI to combine flexible dosing (QD or BID) in PI-naive patients with no food or water restrictions, was approved by the U.S. Food and Drug Administration (FDA) in October 2003.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2004-07-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry